Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients.
The effects of recombinant human erythropoietin (rHuEPO) on endothelial vasoactive substances were evaluated in 19 regular hemodialysis patients. Blood cell counts, plasma endothelin (ET), alpha-human atrial natriuretic peptide (ANP), platelet activating factor (PAF), 6-keto-prostaglandin F1 alpha (PGF1 alpha), and 11-dehydro-thromboxane B2 (TXB2) were evaluated before rHuEPO treatment; at 4, 8, and 12 weeks during treatment; and 5 weeks after the end of treatment. PAF and TXB2 remained unchanged during the study period, PGF1 alpha and ET significantly increased, and ANP decreased along with an improvement in the anemia. Since endothelial vasoactive substances changed significantly during rHuEPO therapy, the correction of anemia with rHuEPO may affect endothelium.
Takayama
K
K
Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan.
Nagai
T
T
Kinugasa
E
E
Akizawa
T
T
Koshikawa
S
S
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood; D001772:Blood Cell Count / Q000187:drug effects; D016232:Endothelins / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010972:Platelet Activating Factor / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000097:blood
D016232:Endothelins; D010972:Platelet Activating Factor; D011994:Recombinant Proteins; D004921:Erythropoietin; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C049235:11-dehydro-thromboxane B2; D009320:Atrial Natriuretic Factor